Has John Guste, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,188 in general payments to John Guste, MD across 270 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Guste, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Guste, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Guste, MD

Plastic and Reconstructive Surgery · Metairie, LANPI 1710121306

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,733 of the $10,188 with a category attached, or 85.7%. 17 manufacturers reported payments, led by AbbVie at 47.0% of the total. 2025 is the largest year on record at $3,360, 2.5 times the $1,356 reported in 2019. Among plastic and reconstructive surgery clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,188in general payments, 2019–2025

Across 270 payments — averaging $37.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$5K
Axogen$3K
Mentor Worldwide LLC$1K
Davol Inc.$245
Galderma Laboratories, L.p.$215
Baxter Healthcare$177
plus $752 from 11 others

What the payments were for

Travel & lodging$1,45514%
Food & beverage$8,73386%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	147	$4,784
Axogen	37	$2,525
Mentor Worldwide LLC	54	$1,491
Davol Inc.	3	$245
Galderma Laboratories, L.p.	7	$215
Baxter Healthcare	5	$177
Stryker	6	$164
Integra Lifesciences Corporation	1	$149
Polynovo North America LLC	1	$113
Organogenesis Inc.	1	$95
Musculoskeletal Transplant Foundation Inc.	1	$55
Sientra, Inc.	2	$40
KCI USA, Inc.	1	$35
Covidien LP	1	$32
Smith+Nephew	1	$29
Pacira Pharmaceuticals Incorporated	1	$20
TELA Bio, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AXOGUARD$3,783
AXOGUARD HA+ NERVE PROTECTOR$1,892
AxoGuard Nerve Cap$1,892
ALLODERM$700
NATRELLE$399
NATRELLE SALINE-FILLED BREAST IMPLANTS$357
INTEGRA$299
ARTOURA Breast Tissue Expander$240
OMNIGRAFT$149
SURGIMEND$149
INTEGRA DERMAL REGENERATION TEMPLATE$149
Phasix Mesh$134
MENTOR MemoryGel Resterilizable Gel Sizer$129
Novosorb BTM$113
MemoryGel Breast Implants$111

How this compares

$10,188 in reported general payments places this provider in the 90th percentile of 45 plastic and reconstructive surgery providers in Louisiana.

See all plastic and reconstructive surgery providers in Louisiana →

Medicare billing

Part B allowed, 2024

$30,834

Medicare patients

Services billed

144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	55	$454
Ondansetron OdtOndansetron	40	$281
Clindamycin Hcl	39	$252
Diazepam	37	$73
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	15	$67

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Metairie

David JansenMetairie$12K
Ravi TandonMetairie$9K
Felix BoppMetairie$8K
Stephen MetzingerMetairie$6K
Simeon WallShreveport$56K
Holly WallShreveport$11K
Omer KaymakcalanNew Orleans$10K
Suma MaddoxNew Orleans$6K
William AukermanNew Orleans$6K
Christopher SmithNew Orleans$5K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →